Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204

Personal Subscription
Become EABM
Become Reviewer

A Cross-Talk Between NFAT and NF-κB Pathways is Crucial for Nickel- Induced COX-2 Expression in Beas-2B Cells

Volume:11   Issue: 5
Pp: 548-559
T. Cai, X. Li, J. Ding, W. Luo, J. Li and C. Huang
DOI: 10.2174/156800911795656001

Targeting Aldose Reductase for the Treatment of Cancer

Volume:11   Issue: 5
Pp: 560-571
R. Tammali, S. K. Srivastava and K. V. Ramana
DOI: 10.2174/156800911795655958

CD44-Targeting for Antitumor Drug Delivery: A New SN-38-Hyaluronan Bioconjugate for Locoregional Treatment of Peritoneal Carcinomatosis

Volume:11   Issue: 5
Pp: 572-585
A. Serafino, M. Zonfrillo, F. Andreola, R. Psaila, L. Mercuri, N. Moroni, D. Renier, M. Campisi, C. Secchieri and P. Pierimarchi
DOI: 10.2174/156800911795655976

The Centrosome: A Target for Cancer Therapy

Volume:11   Issue: 5
Pp: 600-612
M. Mazzorana, G. Montoya and G. B. Mortuza
DOI: 10.2174/156800911795655949

Drug Resistance: Challenges to Effective Therapy

Volume:11   Issue: 5
Pp: 613-623
M. P.V. Shekhar
DOI: 10.2174/156800911795655921

VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

Volume:11   Issue: 5
Pp: 624-653
P. S. Sharma, R. Sharma and T. Tyagi
DOI: 10.2174/156800911795655985